Meek To Drive M&A At Ipsen, Building On Two Major Launches
Executive Summary
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.
You may also be interested in...
Ipsen's Latest Consumer Health Play: Growth Or Attracting Suitors?
Less than a month after investing in Italian nutritional supplement maker Akkadeas Pharma, Ipsen acquires five Sanofi OTC drug brands marketed in Europe, including Prontalgine analgesics available in France.
Ipsen's Latest Consumer Health Play: Growth Or Attracting Suitors?
Less than a month after investing in Italian nutritional supplement maker Akkadeas Pharma, Ipsen acquires five Sanofi OTC drug brands marketed in Europe, including Prontalgine analgesics available in France.
10 Approvals To Watch For In Early 2017
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.